Search Results for: US Rheumatoid Arthritis Treatment Market
Articles
MorphoSys & Immatics Biotechnologies Enter Strategic Alliance August 31, 2015
MorphoSys AG and Immatics Biotechnologies GmbH recently announced a strategic alliance to generate novel antibody-based therapeutics against multiple proprietary cancer...Avexxin Completes Phase I/IIA Study; Achieves PoC In Man With Topical Formulation July 6, 2015
Avexxin's lead compound AVX001 in a topical formulation has shown Proof-of-Concept in man in an ascending dose Phase I/IIa study...SPECIAL FEATURE - Prefilled Syringes & Parenteral Contract Manufacturing: Anticipating the Needs of the Future May 5, 2015
Contributor Cindy H. Dubin speaks with several companies in the prefilled syringe and parenteral manufacturing market that are offering a range of services and systems that cater to today’s issues as well as anticipating the needs of the future.
Can-Fite Signs Multi-Million Dollar Distribution Agreement March 30, 2015
Can-Fite BioPharma Ltd. recently announced it has signed a distribution agreement with Cipher Pharmaceuticals Inc. to distribute Can-Fite's lead drug...SPECIAL FEATURE - Injectable Drug Delivery: Safer, Simpler, Smarter Devices September 4, 2014
Contributor Cindy H. Dubin speaks with some of the leading companies operating in the injectables arena, and discovers this ever-evolving sector is witnessing some very specific and eye-opening trends that are affecting the market’s growth.
ADVANCED DELIVERY DEVICES - Incorporating Patient-Centric Design Into a Novel Anti-Needlestick Safety Device June 5, 2014
Sarah Baer, MBA, says the market for biotechnology drugs continues to grow, and there is a need for pharmaceutical companies to offer injection devices that support both the complex properties of the biologic as well as the needs of the end-user who will be performing the injection.
EXECUTIVE INTERVIEW - Aptar Pharma: From Self-Injection to Auto-Injection November 20, 2013
Pierre Carlotti, Vice-President of Marketing and Communication for Aptar Pharma Prescription Division, talks about the market for auto-injectors and some relevant market trends, and explains how his company went about designing and developing a novel auto-injector.
Aptar Unveils Pro-Ject Technology Platform, Its First Auto-Injector November 10, 2013
Global solution provider of innovative and proven aerosol, injection, and spray delivery systems for prescription drugs, Aptar Pharma Prescription Division...Regeneron & Sanofi Report Positive Top-Line Results October 21, 2013
Sanofi and Regeneron Pharmaceuticals, Inc. recently announced that the Phase III ODYSSEY MONO trial with alirocumab, an investigational monoclonal antibody...SPECIAL FEATURE - Hand Held Devices: New Technologies Right the Wrongs of Earlier Devices October 4, 2013
Contributor Cindy H. Dubin highlights in this annual report that new devices are coming to market that not only address the trends of home care and a need for delivering larger doses, but are also cleaning up the spotty reputation of early stage devices.
Patients & Physicians Express Desire to Switch to Transdermal Drug Delivery July 18, 2013
The $82-billion US drug delivery market is showing no signs of saturation, with major patent expiries, generic competition, tightening FDA...EXECUTIVE INTERVIEW - West Pharmaceutical Services: Celebrating 90 Years of Healthcare Innovation July 10, 2013
Drug Development Executive: Donald E. Morel, Jr., PhD, Chairman and CEO, West, discusses how the company works closely with pharmaceutical and biotechnology companies to deliver life-changing therapies safely and effectively to patients.
2/13/2013 February 11, 2013
Frost & Sullivan Sees Urgent Need for Cancer Diagnostics Tests; Finds Unmet Need for Key Disorders The range of potential...Lycera Expands Partnership With Merck; Potential $600-Million Deal February 11, 2013
Lycera Corp. recently announced a collaboration agreement with Merck to discover, develop, and commercialize small-molecule therapies directed to selected...1/9/2013 January 3, 2013
Ultragenyx Secures $75 Million for Ultra-Rare Diseases Ultragenyx Pharmaceutical Inc. recently announced the successful completion of a $75-million Series B...Independent AbbVie Officially Launches January 3, 2013
 AbbVie recently marked its launch as an independent biopharmaceutical company, with employees from more than 40 countries and patients...12/12/2012 December 10, 2012
TNF Inhibitors Lay Groundwork for Next-Generation of Disease-Modifying Anti-Rheumatic Drugs The challenges inherent in the pharmacological management of rheumatic diseases...TNF Inhibitors Lay Groundwork for Next-Generation of Disease-Modifying Anti-Rheumatic Drugs December 10, 2012
The challenges inherent in the pharmacological management of rheumatic diseases have stoked huge demand for drug classes with excellent safety...11/14/2012 November 8, 2012
A Note to The Pharmaceutical Industry Upon The Re-Election of Barack Obama By: Matthew Herper, Forbes Staff, mherper@forbes.com I've covered...10/30/2012 October 25, 2012
Arthritis Signifies a Vast Untouched Market, Finds Frost & Sullivan Tumor necrosis factor (TNF) inhibitors are currently the only therapeutic...
